ESMO Sarcoma and Rare Cancers 2023 | Unmet needs and the future of tumor agnostic treatment

Claudia María Valverde Morales, MD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the remaining unanswered questions concerning the optimization of tumor agnostic therapy. Dr Valverde emphasizes the elusive biology shrouding such tumors, and the necessity to improve upon our current knowledge regarding their unique pathophysiology. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.